NCT05514132 2026-03-09
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
AstraZeneca
Pyxis Oncology, Inc
AstraZeneca
RemeGen Co., Ltd.
Shandong Boan Biotechnology Co., Ltd
AstraZeneca
RemeGen Co., Ltd.
Biotheus Inc.
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
AstraZeneca
AstraZeneca
Zucero Pty Ltd
Zucero Pty Ltd
Heidelberg Pharma AG
Heidelberg Pharma AG